Anti-CD25 treatment and FOXP3-positive regulatory T cells in heart transplantation

Transplant Immunology

Volumn 18, Issue 1, 2007, Pages 13-21

  Vlad, G ^a   Ho, E K ^a   Vasilescu, E R ^a   Fan, J ^a   Liu, Z ^a   Cai, J W ^a   Jin, Z ^a   Burke, E ^a   Deng, M ^a   Cadeiras, M ^a   Cortesini, R ^a   Itescu, S ^a   Marboe, C ^a   Mancini, D ^a   Suciu Foca, N ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Daclizumab; FOXP3; Heart transplantation; Rejection; T regulatory cells

Indexed keywords

CYCLOSPORIN; DACLIZUMAB; INTERLEUKIN 2 RECEPTOR ALPHA; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TRANSCRIPTION FACTOR FOXP3;

ACUTE GRAFT REJECTION; ADULT; AGED; ANTIBODY PRODUCTION; ARTICLE; COHORT ANALYSIS; DOSE RESPONSE; DRUG DOSE COMPARISON; FEMALE; GRAFT FAILURE; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE;

ADOLESCENT; ADULT; AGED; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HEART TRANSPLANTATION; HLA ANTIGENS; HUMANS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; MALE; MIDDLE AGED; T-LYMPHOCYTES, REGULATORY;

EID: 34250356020     PISSN: 09663274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trim.2007.03.001     Document Type: Article

References (42)

1. Kirk A.D. Induction immunosuppression. Transplantation 82 5 (2006) 593-602
2. Sandrini S. Use of IL-2 receptor antagonists to reduce delayed graft function following renal transplantation: a review. Clin Transplant 19 6 (2005) 705-710
3. Figueras J., Prieto M., Bernardos A., Rimola A., Suarez F., de Urbina J.O., et al. Daclizumab induction and maintenance steroid-free immunosuppression with mycophenolate mofetil and tacrolimus to prevent acute rejection of hepatic allografts. Transpl Int 19 8 (2006) 641-648
4. Vo A.A., Toyoda M., Peng A., Bunnapradist S., Lukovsky M., and Jordan S.C. Effect of induction therapy protocols on transplant outcomes in crossmatch positive renal allograft recipients desensitized with IVIG. Am J Transplant 6 10 (2006) 2384-2390
5. Sakaguchi S. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 22 (2004) 531-562
6. Shevach E.M. CD4+ CD25+ suppressor T cells: more questions than answers. Nat Rev 2 6 (2002) 389-400
7. Bluestone J.A., and Abbas A.K. Natural versus adaptive regulatory T cells. Nat Rev 3 3 (2003) 253-257
8. Vlad G., Cortesini R., and Suciu-Foca N. License to heal: bidirectional interaction of antigen-specific regulatory T cells and tolerogenic APC. J Immunol 174 10 (2005) 5907-5914
9. Manavalan J.S., Rossi P.C., Vlad G., Piazza F., Yarilina A., Cortesini R., et al. High expression of ILT3 and ILT4 is a general feature of tolerogenic dendritic cells. Transpl Immunol 11 3-4 (2003) 245-258
10. Roncarolo MG, Gregori S, Levings M. Type 1 T regulatory cells and their relationship with CD4+ CD25+ T regulatory cells. Novartis Foundation Symposium 2003; 252:115-27; discussion 127-31, 203-110.
11. Levings M.K., Gregori S., Tresoldi E., Cazzaniga S., Bonini C., and Roncarolo M.G. Differentiation of Tr1 cells by immature dendritic cells requires IL-10 but not CD25+ CD4+ Tr cells. Blood 105 3 (2005) 1162-1169
12. Endharti A.T., Rifa I.Ms., Shi Z., Fukuoka Y., Nakahara Y., Kawamoto Y., et al. Cutting edge: CD8+ CD122+ regulatory T cells produce IL-10 to suppress IFN-gamma production and proliferation of CD8+ T cells. J Immunol 175 11 (2005) 7093-7097
13. Reed E.F., Demetris A.J., Hammond E., Itescu S., Kobashigawa J.A., Reinsmoen N.L., et al. Acute antibody-mediated rejection of cardiac transplants. J Heart Lung Transplant 25 2 (2006) 153-159
14. Lietz K., John R., Burke E., Schuster M., Rogers T.B., Suciu-Foca N., et al. Immunoglobulin M-to-immunoglobulin G anti-human leukocyte antigen class II antibody switching in cardiac transplant recipients is associated with an increased risk of cellular rejection and coronary artery disease. Circulation 112 16 (2005) 2468-2476
15. Vasilescu E.R., Ho E.K., de la Torre L., Itescu S., Marboe C., Cortesini R., et al. Anti-HLA antibodies in heart transplantation. Transpl Immunol 12 2 (2004) 177-183
16. Marboe C.C., Billingham M., Eisen H., Deng M.C., Baron H., Mehra M., et al. Nodular endocardial infiltrates (Quilty lesions) cause significant variability in diagnosis of ISHLT Grade 2 and 3A rejection in cardiac allograft recipients. J Heart Lung Transplant 24 7 Suppl (2005) S219-S226
17. Vasilescu E.R., Ho E.K., Colovai A.I., Vlad G., Foca-Rodi A., Markowitz G.S., et al. Alloantibodies and the outcome of cadaver kidney allografts. Hum Immunol 67 8 (2006) 597-604
18. Itescu S., Burke E., Lietz K., John R., Mancini D., Michler R., et al. Intravenous pulse administration of cyclophosphamide is an effective and safe treatment for sensitized cardiac allograft recipients. Circulation 105 10 (2002) 1214-1219
19. Liang K.Y., and Zeger S.L. Longitudinal data analysis using generalized linear models. Biometrika 73 (1986) 13-22
20. Kalbfleisch J.D., and Prentice R.L. The statistical analysis of failure time data. second edition (2002), Wiley, New York
21. Liu Z., Tugulea S., Cortesini R., and Suciu-Foca N. Specific suppression of T helper alloreactivity by allo-MHC class I-restricted CD8+ CD28- T cells. Int Immunol 10 6 (1998) 775-783
22. Chang C.C., Ciubotariu R., Manavalan J.S., Yuan J., Colovai A.I., Piazza F., et al. Tolerization of dendritic cells by T(S) cells: the crucial role of inhibitory receptors ILT3 and ILT4. Nat Immunol 3 3 (2002) 237-243
23. Manavalan J.S., Kim-Schulze S., Scotto L., Naiyer A.J., Vlad G., Colombo P.C., et al. Alloantigen specific CD8+ CD28- FOXP3+ T suppressor cells induce ILT3+ ILT4+ tolerogenic endothelial cells, inhibiting alloreactivity. Int Immunol 16 8 (2004) 1055-1068
24. Cobbold S.P., Graca L., Lin C.Y., Adams E., and Waldmann H. Regulatory T cells in the induction and maintenance of peripheral transplantation tolerance. Transpl Int 16 2 (2003) 66-75
25. Scotto L., Naiyer A.J., Galluzzo S., Rossi P., Manavalan J.S., Kim-Schulze S., et al. Overlap between molecular markers expressed by naturally occurring CD4+ CD25+ regulatory T cells and antigen specific CD4+ CD25+ and CD8+ CD28- T suppressor cells. Hum Immunol 65 11 (2004) 1297-1306
26. Reinders M.E., Sho M., Izawa A., Wang P., Mukhopadhyay D., Koss K.E., et al. Proinflammatory functions of vascular endothelial growth factor in alloimmunity. J Clin Invest 112 11 (2003) 1655-1665
27. Ruprecht C.R., and Lanzavecchia A. Toll-like receptor stimulation as a third signal required for activation of human naive B cells. Eur J Immunol 36 4 (2006) 810-816
28. Kim-Schulze S., Scotto L., Vlad G., Piazza F., Lin H., Liu Z., et al. Recombinant Ig-like transcript 3-Fc modulates T cell responses via induction of Th anergy and differentiation of CD8+ T suppressor cells. J Immunol 176 5 (2006) 2790-2798
29. Liu Z., Tugulea S., Cortesini R., Lederman S., and Suciu-Foca N. Inhibition of CD40 signaling pathway in antigen presenting cells by T suppressor cells. Hum Immunol 60 7 (1999) 568-574
30. Wood K.J., and Sakaguchi S. Regulatory T cells in transplantation tolerance. Nat Rev 3 3 (2003) 199-210
31. Zwar T.D., van Driel I.R., and Gleeson P.A. Guarding the immune system: suppression of autoimmunity by CD4+ CD25+ immunoregulatory T cells. Immunol Cell Biol 84 6 (2006) 487-501
32. Kapp J.A., Honjo K., Kapp L.M., Xu X., Cozier A., and Bucy R.P. TCR transgenic CD8+ T cells activated in the presence of TGFbeta express FoxP3 and mediate linked suppression of primary immune responses and cardiac allograft rejection. Int Immunol 18 11 (2006) 1549-1562
33. Liu J., Liu Z., Witkowski P., Vlad G., Manavalan J.S., Scotto L., et al. Rat CD8+ FOXP3+ T suppressor cells mediate tolerance to allogeneic heart transplants, inducing PIR-B in APC and rendering the graft invulnerable to rejection. Transpl Immunol 13 4 (2004) 239-247
34. Banham A.H., Powrie F.M., and Suri-Payer E. FOXP3+ regulatory T cells: current controversies and future perspectives. Eur J Immunol 36 11 (2006) 2832-2836
35. Beyer M., and Schultze J.L. Regulatory T cells in cancer. Blood 108 3 (2006) 804-811
36. Pillai V., Ortega S.B., Wang C.K., and Karandikar N.J. Transient regulatory T-cells: a state attained by all activated human T-cells. Clin Immunol 123 1 (2007) 18-29
37. Wang J., Ioan-Facsinay A., van der Voort E.I., Huizinga T.W., and Toes R.E. Transient expression of FOXP3 in human activated nonregulatory CD4(+) T cells. Eur J Immunol 37 1 (2007) 129-138
38. Yu H., Kortylewski M., and Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev 7 1 (2007) 41-51
39. Gonzalez-Rey E., Chorny A., Fernandez-Martin A., Ganea D., and Delgado M. Vasoactive intestinal peptide generates human tolerogenic dendritic cells that induce CD4 and CD8 regulatory T cells. Blood 107 9 (2006) 3632-3638
40. Rezvani K., Mielke S., Ahmadzadeh M., Kilical Y., Savani B.N., Zeilah J., et al. High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT. Blood 108 4 (2006) 1291-1297
41. Ziegler S.F. FOXP3: of mice and men. Annu Rev Immunol 24 (2006) 209-226
42. Kreijveld E., Koenen H.J., Klasen I.S., Hilbrands L.B., and Joosten I. Following anti-CD25 treatment, a functional CD4+ CD25+ regulatory T-cell pool is present in renal transplant recipients. Am J Transplant 7 1 (2007) 249-255